Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

NILOTINIB vs NIRSEVIMAB-ALIP: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

NILOTINIB vs NIRSEVIMAB-ALIP: Safety Overview

Metric NILOTINIB NIRSEVIMAB-ALIP
Total FAERS Reports 23,171 783
Deaths Reported 4,543 32
Death Rate 19.6% 4.1%
Hospitalizations 4,846 281
Average Patient Age 56.5 yrs 3.3 yrs
% Female Patients 47.7% 46.3%
FDA Approval Date Dec 15, 2025 N/A
Manufacturer Novadoz Pharmaceuticals LLC N/A
Route ORAL N/A
Marketing Status Prescription Prescription